Literature DB >> 18671778

Nonsteroidal anti-inflammatory drug use as a risk factor for gastro-oesophageal reflux disease: an observational study.

P Ruszniewski1, C Soufflet, P Barthélémy.   

Abstract

BACKGROUND: Although the associations between nonsteroidal anti-inflammatory drugs (NSAIDs) and peptic ulcer disease or dyspepsia are well established, fewer data exist concerning the relationship between NSAIDs and gastro-oesophageal reflux disease (GERD). AIM: To examine the relationship between NSAIDs and GERD.
METHODS: A self-administered questionnaire covering NSAID use and GERD symptoms (heartburn and acid regurgitation) was sent to a representative national sample of 10,000 French adults (> or = 18 years) between 14 October and 21 November 2005. Risk factors associated with GERD were identified by logistic regression analysis in respondents who were not taking aspirin or proton pump inhibitors.
FINDINGS: A total of 7259 completed questionnaires were returned of which 6823 were evaluable. Overall, 2262 respondents (33%) reported using NSAIDs during the previous 3 months. The lifetime and 3-month prevalence rates of GERD symptoms were 37% and 21% respectively. GERD symptoms were significantly more common among NSAID users than among non-users (27% vs. 19%, P < or = 0.001) and a similar trend was seen for aspirin use. Proton pump inhibitors were received by 31% of respondents who reported experiencing GERD symptoms within the previous 3 months compared with 6% of those without symptoms (P < 0.01); however, only 20% of NSAID-treated respondents were receiving proton pump inhibitors. NSAID use, age and female gender were independent predictors of GERD symptoms.
CONCLUSION: NSAID or aspirin use is a significant risk factor for GERD symptoms.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18671778     DOI: 10.1111/j.1365-2036.2008.03821.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  9 in total

1.  Non-prescription treatment of NSAID induced GORD by Australian pharmacies: a national simulated patient study.

Authors:  Brett MacFarlane; Andrew Matthews; Jenny Bergin
Journal:  Int J Clin Pharm       Date:  2015-05-14

2.  Isolation of Mycobacterium fortuitum in sputum specimens of a patient with chronic cough: Is it clinically significant?

Authors:  M R Radzniwan; H Tohid; S Ahmad; Ali F Mohd; F Md Anshar
Journal:  Malays Fam Physician       Date:  2014-12-31

3.  Increased incidence of gastroesophageal reflux disease in patients with chronic hepatitis B virus infection.

Authors:  Ching-Sheng Hsu; Chia-Chi Wang; Pin-Chao Wang; Hans Hsienhong Lin; Tai-Chung Tseng; Chien-Hwa Chen; Wei-Chih Su; Chun-Jen Liu; Chi-Ling Chen; Ming-Yang Lai; Pei-Jer Chen; Ding-Shinn Chen; Jia-Horng Kao
Journal:  Hepatol Int       Date:  2010-07-01       Impact factor: 6.047

4.  A double-blind, controlled study comparing lafutidine with placebo and famotidine in Japanese patients with mild reflux esophagitis.

Authors:  Shuichi Ohara; Ken Haruma; Yoshikazu Kinoshita; Motoyasu Kusano
Journal:  J Gastroenterol       Date:  2010-07-15       Impact factor: 7.527

5.  In Vitro and In Vivo Effects of Nonsteroidal Anti-inflammatory Drugs and Aspirin on Rabbit Esophageal Epithelium.

Authors:  Sezgi Kıpçak; Doğa Çağanoğlu; Pelin Ergün; Serhat Bor
Journal:  Turk J Gastroenterol       Date:  2022-03       Impact factor: 1.555

6.  Prevalence of gastroesophageal reflux disease symptoms and related factors in patients with rheumatoid arthritis.

Authors:  Akihide Nampei; Kenrin Shi; Kosuke Ebina; Tetsuya Tomita; Kazuomi Sugamoto; Hideki Yoshikawa; Makoto Hirao; Jun Hashimoto
Journal:  J Clin Biochem Nutr       Date:  2013-02-06       Impact factor: 3.114

7.  Risk factors for persistent and new chronic opioid use in patients undergoing total hip arthroplasty: a retrospective cohort study.

Authors:  Maria C S Inacio; Craig Hansen; Nicole L Pratt; Stephen E Graves; Elizabeth E Roughead
Journal:  BMJ Open       Date:  2016-04-29       Impact factor: 2.692

8.  Risk Factors for Gastroesophageal Reflux Disease in Saudi Arabia.

Authors:  Ali Mesfer Alkhathami; Abdulrahman Ahmad Alzahrani; Mohammed Abdullah Alzhrani; Obaidallah Buraykan Alsuwat; Mohammad Eid Mahmoud Mahfouz
Journal:  Gastroenterology Res       Date:  2017-10-26

9.  Gastroesophageal reflux disease in a typical African population: a symptom-based multicenter study.

Authors:  Sylvester Chuks Nwokediuko; Olusegun Adekanle; Adegboyega Akere; Abdulfatai Olokoba; Chiedozie Anyanechi; Sabo Mustapha Umar; Abubakar Maiyaki; Uchenna Ijoma; Olive Obienu; Augustine Uhunmwangho; Dennis Ndububa
Journal:  BMC Gastroenterol       Date:  2020-04-15       Impact factor: 3.067

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.